ArticleFrontiers in immunology2020
Human Commensal
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses - a randomized, placebo-controlled clinical trial.Immunologic research · 2024Trial
- Review
- The gut microbiota-miRNA axis in multiple sclerosis: Mechanisms and therapeutic potentials.Folia microbiologica · 2026Review
- IL-17A deficiency in HLA-DR3 transgenic mice enriches beneficial Prevotella species in gut to promote Tregs and reduce CNS autoimmunity.Microbiome · 2026Article
- Multi-omics analysis reveals the critical role of gut microbiota related tryptophan and glutathione metabolism in sepsis-associated encephalopathy.BMC microbiology · 2026Article
- Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum.Frontiers in immunology · 2026Review
- Redefining multiple sclerosis therapy through microbial immunomodulation and epigenetic control.Journal of translational autoimmunity · 2025Review
- Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2025Review
- Decoding Fibromyalgia: Genetic Insights into Gut and Immune System Interactions.Journal of pain research · 2025Article
- Review
- In Situ Expression of YakVeterinary sciences · 2024Article
- Oral microbiome dysbiosis may be associated with intra cranial aneurysms.BMC oral health · 2024Article
- Gut Microbiota Composition Is Causally Linked to Multiple Sclerosis: A Mendelian Randomization Analysis.Microorganisms · 2024Article
- Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis.Scientific reports · 2024Article
- Relationship between gut microbiota and multiple sclerosis: a scientometric visual analysis from 2010 to 2023.Frontiers in immunology · 2024Article
- Substance P Reduces Infarct Size and Mortality After Ischemic Stroke, Possibly Through the M2 Polarization of Microglia/Macrophages and Neuroprotection in the Ischemic Rat Brain.Cellular and molecular neurobiology · 2023Article
- Prevotella histicola suppresses ferroptosis to mitigate ethanol-induced gastric mucosal lesions in mice.BMC complementary medicine and therapies · 2023Article
- The Role of Gut Dysbiosis and Potential Approaches to Target the Gut Microbiota in Multiple Sclerosis.CNS drugs · 2023Review
- The gut microbiota in multiple sclerosis varies with disease activity.Genome medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Gut microbiota has emerged as an important environmental factor in the pathobiology of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS). Both genetic and environmental factors have been shown to play an important role in MS. Among genetic factors, the human leukocyte antigen (HLA) class II allele such as HLA-DR2, DR3, DR4, DQ6, and DQ8 show the association with the MS. We have previously used transgenic mice expressing MS susceptible HLA class II allele such as HLA-DR2, DR3, DQ6, and DQ8 to validate significance of HLA alleles in MS. Although environmental factors contribute to 2/3 of MS risk, less is known about them. Gut microbiota is emerging as an imporatnt environmental factor in MS pathogenesis. We and others have shown that MS patients have distinct gut microbiota compared to healthy control (HC) with a lower abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.